SlideShare une entreprise Scribd logo
1  sur  34
A R O C K R E P O R T B Y
THE ENTREPRENEUR’S GUIDE !
TO HOSPITAL PARTNERSHIPS
A R O C K R E P O R T B Y
This document should serve as a guide for entrepreneurs as they navigate partnering with health
care providers. This first draft was compiled after 22 interviews with entrepreneurs, hospital
administrators, investors, lawyers, clinicians and researchers. This is a living document, intended
to grow and improve with your input. 

Authors:
•  Sasha Buscho, Harvard MPH
•  Christina Chang, Harvard MBA
•  Aenor Sawyer, MD, UCSF Clinician

Editor
•  Halle Tecco, Rock Health CEO
•  Malay Gandhi, Rock Health Mentor-in-Residence
•  Adam Dole, Mayo Clinic 
About this Guide
ROCK HEALTH is powering the future of the digital health ecosystem, bringing together the
brightest minds across disciplines to build better solutions. Rock Health funds and
supports startups building the next generation of technologies transforming healthcare.
ROCK HEALTH partners include Alexandria Real Estate Equities, Boehringer Ingelheim,
Fenwick & West, GE, Genentech, Harvard Medical School, Kaiser Permanente, Kleiner
Perkins Caufield & Byers, Mayo Clinic, Mohr Davidow Ventures, Montreux Equity Partners,
NEA, Ogilvy Public Relations, Qualcomm Life and UCSF.
LEARN MORE AT rockhealth.com
How can startups and health
care providers partner more
effectively to pilot and
commercialize digital health
innovations?
A R O C K R E P O R T B Y
BACKGROUND
Scope of Guidelines
The goal of the pilot is two fold:
validation and progression to full-
scale commercialization
The digital healthcare pilot is defined
as a product implementation trial with
end-users / potential customers
Definition
Goal
A R O C K R E P O R T B Y
KEY CHALLENGES
Divergent Risk Profiles
Health care providers have many priorities
including health outcomes, patient safety
and security and best practices research.
Startups prioritize new practices, adoption
and growth
A R O C K R E P O R T B Y
KEY CHALLENGES
Divergent Risk Profiles
Differing Motivations
Health care providers have many priorities
including health outcomes, patient safety
and security and best practices research.
Startups prioritize new practices, adoption
and growth
Some “motivators” for provider
participation, including shared intellectual
property, equity, and key metrics, may not
align with startup goals
A R O C K R E P O R T B Y
KEY CHALLENGES
Divergent Risk Profiles
Differing Motivations
Distinct Cultures
Startups and providers have significant
differences in availability, team size,
decision-making dynamics, and overall
timelines
Health care providers have many priorities
including health outcomes, patient safety
and security and best practices research.
Startups prioritize new practices, adoption
and growth
Some “motivators” for provider
participation, including shared intellectual
property, equity, and key metrics, may not
align with startup goals
A R O C K R E P O R T B Y
KEY CHALLENGES
Divergent Risk Profiles
Differing Motivations
Some “motivators” for provider
participation, including shared intellectual
property, equity, and key metrics, may not
align with startup goals
Distinct Cultures
Startups and providers have significant
differences in availability, team size,
decision-making dynamics, and overall
timelines
Complex Regulations
Institutions enforce a multitude of
regulations, both internal (e.g. IRB) and
external (e.g. FDA), which are difficult to
interpret without internal champions
Health care providers have many priorities
including health outcomes, patient safety
and security and best practices research.
Startups prioritize new practices, adoption
and growth
A R O C K R E P O R T B Y
Deployment Strategy: Pushing a product or service to
the patient for testing is different than getting hospitals
or clinicians to adopt and distribute technologies
themselves
KEY CONSIDERATION:
Consumer-Facing VS. Enterprise Solutions
Purpose: Pilots for B2B startups are needed to
demonstrate outcomes that motivate enterprise buyers
while B2C startups can gain significant brand
recognition from validation within a provider setting
A R O C K R E P O R T B Y
Hospitals have many established
systems that if leveraged properly,
can represent significant distribution
channels for new technologies.
Whether you’re a B2B or B2C, it is
important to consider how a
startup’s product or service could
be integrated into the existing
hospital systems.

- Adam Dole, Mayo Clinic
A R O C K R E P O R T B Y
KEY CONSIDERATION:
A device startup likely follows a rigorous timeline, runs pilots that
require IRB/human subjects approval, patenting, publishing,
FDA clearance and approval
Medical Devices VS. Digital Health 
A digital health startup may be eligible for an expedited or
exempt IRB and less-rigorous regulatory process. BUT they
may also have a harder time connecting with a provider, due
to difficulties such as clinician workflow integration, difficult to
measure outcomes, IT infrastructure issues and misaligned
incentives

A R O C K R E P O R T B Y
Clinical evaluation focuses on product usability, adoption and/or
impact. This can require rigorous scientific methods and often a
longer, more intimate relationship with the hospital partner

Business evaluation measures how the market values a
company’s products and services. This requires clear
negotiations upfront around the hurdles and milestones
necessary to move from pilot to commercialization
Clinical Efficacy VS. Business Model Evaluation
KEY CONSIDERATION:
A pilot should test both the clinical efficacy and business model of the
product or service. But these tests can be quite different:
A R O C K R E P O R T B Y
PILOT TIMELINE
LAUNCH
customer building
BUILD
validation
SCALE
growth
MATURE
sustainability
CONTEXT	
  	
  
I. Pre-Pilot
 II. Pilot Design
 III. Iteration	
   IV. Validation	
  
startup lifecycle
4 PHASES
4-8 weeks
 2-4 months
 3-6 months
 ongoing
pilot start
6-12 months for
large scale testing
A R O C K R E P O R T B Y
PHASE 1:
PRE-PILOT
The startup has to involve
clinical guidance early and
often, starting from the
early brainstorming portion. 

From experience – we will
have startups that focus so
much on the tech-side,
then come to the frontlines
to test it, and we realize it’s
a mismatch for the
problem.

-- Aenor Sawyer, UCSF
I. Pre-Pilot
 II. Pilot Design
 III. Iteration	
   IV. Validation	
  
Clearly define what unmet need startup is looking to impact. 
Target Appropriate Hospital System (teaching hospital, a general
hospital, a specialty hospital, or a clinic)
§  Consider the goals of your pilot
§  Does the payment system (pay-for performance vs. fee-for-service) matter?
Understand how decisions are made, and who makes them 
§  How is the leadership structured? 
§  Who needs to be on-board to approve decisions?
Find a Champion
§  Network in your field, and find the right person(s) for your partnership. Discuss 
their interests, availability and commitments
§  Champions are typically found through personal contacts or literature searches 
for researchers working on a related topic 
Complete HIPAA training, IRB / research training and scope out relevant
FDA regulations
File for a provisional patent
Decide if the hospital partner will be an inventor-contributor or a data
collector
 A R O C K R E P O R T B Y
The pilot successes we've had happened
when we did all of the legwork for our
internal champion upfront—preparing for
the IRB, designing a sufficiently powerful
study—versus trying to figure out ways
around it.

- Joseph Abrahamson, CTO of Reify Health
Collaboration in healthcare
often leads to co-ownership
of the patents, which
sounds great but will scare
off investors (since the
hospital can license your
competitor).

One solution is to file a
provisional patent
application before starting
the collaboration. 
-Jeffrey Schox, Startup Patent
Lawyer
PHASE 2: PILOT DESIGN
The start-up needs to figure out who their customer is, and what
evidence they need to sell to those customers.

Digital healthcare startups can generally be classified as adding value to the healthcare
system either on the delivery or administration side.
Pilots for administrative startups need to create a business case
about improving bottom-line performance of the health care
provider, e.g. higher productivity, lowered costs, improved
revenue or cash flow.
Startups focused in the delivery side require comparison data
on integration, usability and clinical outcomes. Here – depth of
rigor and scientific analysis are critical. A randomized-control
trial is not always feasible, but generally considered the gold
standard for reliable clinical evidence.
A R O C K R E P O R T B Y
Pre-Pilot
 Pilot Design
 Iteration	
   Validation	
  
Determine: Roles, scope, incentives
§  Incentives for hospital involvement can include: publishing rights, equity, revenue-
share, licensing, training opportunities for clinicians on mHealth
§  Collaborate with partners to outline how much time is required by individuals from 
both groups…get specific. 
§  Clearly define the relationship. Is this a pilot? Partnership? Advisory position?
Design Study
§  Define the purpose of the study, and the appropriate research methods for that 
purpose. The pilot should be designed to directly test hypotheses. What is your 
study design (e.g. RCT, observational)?
Set goals and metrics
§  Measure the right processes and outcomes to test your driving hypotheses. 
Substantiate a case for moving from pilot to full-scale commercialization. 
Create timelines
Complete institutional regulatory forms
§  Including: IT Security Compliance / Confidentiality Agreement / IRB Approval / 
HIPAA certification
Determine disclosure policies 
§  If you’re not ready to “go public” with the product, prepare an NDA
Set budget and formalize all cost-sharing
What can really take a long
time inside of a healthcare
institution, is coordinating the
terms of the relationship and
structuring the agreement.
Every time a decision needs to
be made many stakeholders
need to be consulted. 

The more proactive and
insightful a startup can be
about what they want to get
out of their relationship with the
clinical partner the faster the
relationship can move.

- Adam Dole, Mayo Clinic
The biggest challenge we faced
was scheduling time with the
clinicians. We really depended
on our internal champion to
stay enthusiastic and engaged,
and to share the product with
his colleagues.

- Michael Pan, Nephosity
PHASE 3: ITERATION
During Phase 3, the initial small-scale roll out grows. Feedback
and input on the product are discussed and incorporated.
Evidence accumulates. The evolving product is tested in larger
populations.
Pre-Pilot
 Pilot Design
 Iteration	
   Validation	
  
Relationship management:
§  Once the pilot launches, the partners need to monitor and analyze data together,
which involves regular communication
§  Consider how the hospital staff is interacting with your technology, and adjust pain-
points to facilitate ease of use
Stage expansion plans 
§  Set check-points as the pilot grows. How many people will be included in the pilot?
When will they be contacted? How many times will you iterate?
§  Note that iterations may require further IRB and regulatory approvals
Data analysis
§  The pilot should test hypotheses you have already formed. Know who will lead the
data analysis, and set a schedule to check results
File for a patent
§  The patent application should be filed within 12 months of the provisional
Acquire appropriate funding to fuel growth
A R O C K R E P O R T B Y
PHASE 4: VALIDATION
The startup should have sufficient evidence to sell to their
customers, allowing the pilot to transform into full-scale
commercialization

“Sufficient evidence” can take many forms, depending on the pilot design (see Phase 2) 

Administrative pilots will find useful validation metrics in the
changes in bottom-line performance of the hospital, provider
usage, and user satisfaction 
Clinical pilots will find validation through rigorous and
repeatable scientific research. Publication in a peer-reviewed
journal is one reliable validation of clinical studies
A R O C K R E P O R T B Y
Pre-Pilot
 Pilot Design
 Iteration	
   Validation	
  
Finalize validation criteria specific to your product or service
Draft and publish a final report
§  Who will be included as authors?
§  How will the relationship be described?
§  Which results are included in the report?
§  Who is the target audience for the publication?

File for FDA approval if product claims to treat or diagnose
§  Inform FDA at least 90 days in advance of marketing a medical device
A final report allows you to stick a flag in your research. If it’s truly
novel and successful then it's going to cause a splash when it's
published and your team should be prepared for that. Understand
that research papers are important components of the domino
effect. 
– Reify Health
A R O C K R E P O R T B Y
§  Target appropriate
hospital system
§  Study hospital
structure/processes
§  Find a champion
§  Conduct research
§  Determine: purpose, roles,
scope, incentives 
§  Set goals and metrics
§  Create timelines
§  User recruitment
§  Sign: BAA, Letter of Intent
§  Staging expansion
plans 
§  Data analysis
§  Final Report 
Relationship
Management
§  HIPAA training
§  IRB training
§  FDA scoping
§  Conflict of interests
§  IT Security Compliance
§  Confidentiality Agreement
§  IRB Approval
§  HIPAA certification
•  Text 
•  
•  
Privacy/
Regulatory
§  File provisional
patent application
§  Consider disclosure policies
(NDA if necessary)
§  File for patent
(within 12 mos)
Legal
§  Seed funding
§  Grant Application
§  Budget
§  Budget with hospitals
§  Cost-sharing if applicable
§  Acquire
appropriate funds
Fund-
raising
 KEY
Startup
Startup / Provider
collaboration
SUMMARY
Pre-Pilot
 Pilot Design
 Iteration	
   Validation	
  
§  File for FDA clearance
if applicable
Stories from the trenches
Product development and pilot testing can take many forms. Below are some
creative ways entrepreneurs have hacked the system...
Before we invested time and resources in a pilot, we
recruited users on Craigslist to test our products and
give us feedback. Once the product was developed
and tested, we took it to the hospitals.
We just gave the doctors iPads, and in return they
agreed to give us feedback. We got the pilot running
at that hospital in two weeks...
Researchers at Mass General were interested in
running these trials and publishing the results,
because we were taking a proven scientific
mechanism, and applying it to digital health. It could
have major scientific implications.
A R O C K R E P O R T B Y
§  Find a champion:
CEO utilized his
network, connected
with an interested
psychologist at
HMS / Mass Gen.
§  Researcher incentives: career
advancement, publishing
§  Survey design: pre/post test
§  Timelines, scope and roles
set, BAA discussed
§  Users recruited from clinic
§  Expansion: second
pilot with
randomized control
trial 
§  Data analysis and
first publication led
by PI
§  First paper to be
published in peer-
reviewed journal

Relationship
Management
§  HIPAA: made product
and data anonymous
§  IRB: used previously
successful proposal
§  Conflict of interest:
Researcher opted-out
of medical advisory &
stock options
§  IT Security Compliance approved
§  Confidentiality Agreement: Drafted
between hospital and patients,
data stored anonymously
§  IRB Approval: Takes 1.5 months
Privacy/
Regulatory
§  Grant Application:
Jointly filed, with
researcher as PI and
startup CEO as
“advisor”
§  Received grant to cover
research costs
 
Fund-
raising
 KEY
Pre-Pilot
 Pilot Design
 Iteration	
   Validation	
  
A Successful Partnership: 
Cognitive Health Innovations & Harvard Medical System
§  Received second grant for a
3rd trial 
§  Patent not currently
in process
Legal
A R O C K R E P O R T B Y
APPENDIX
A R O C K R E P O R T B Y
Purpose
§  What is the purpose of the partnership / pilot?
§  What user needs does this product fulfill?
§  What are you trying to validate with this partnership / pilot?
Scope
§  What is the expected timeline for this pilot / partnership?
§  How will this project be funded?
§  What specific actions / access / deliverables do you need from the health care
provider? (Specify practice area / specialty, content, clinical protocol, etc.)
§  What types of specialists or sub-specialists will be needed? What part of the
technology will the specialists evaluate?
Roles
§  Who are the members of the startup and provider teams, and what are their specific
roles (teach, train, data collection etc.)?
Before approaching a hospital, prepare answers the questions below. Consider this a
collaborative process and working document.
DO YOUR HOMEWORK
A R O C K R E P O R T B Y
Roles (cont)
§  How will each stakeholder benefit from this pilot?
§  How will the startup describe their relationship with the provider to external parties?
Is this a “partnership?” A “pilot?” A “co-investigation?”
Incentives:
§  Why should the provider invest time and resources in this? Will they benefit in terms
of physical content (articles, etc), specific clinical protocols, advisory roles, etc.?
§  How, specifically, can the provider add strategic value to this product? 
§  What, if any, advisory role will the provider play?
§  What patents does the startup have that would attract the health care provider?
(Remember to discuss patent and IP rights early)
§  What benefits will the hospital receive? (equity, revenue share, licensing, etc)
§  Is there a transition where the provider / customers will start to pay for the product?
When? Will the pilot providers get a deal?
§  Who will have access to the data? Who can publish the data?
DO YOUR HOMEWORK (cont)
A R O C K R E P O R T B Y
§  Business Associates Agreement
§  Proposal of Scope Examples
§  IT Security Compliance Checklist
§  HIPAA Compliance Checklist
§  Confidentiality Agreement
§  Non-Disclosure Agreement
§  IRB Process and Guideline Examples
rockhealth.com/resources
RESOURCES
A R O C K R E P O R T B Y
§  Darren Hite, Aberdare Ventures
§  Aman Bhandari, Health and Human
Services
§  Greg Downing, Health and Human
Services
§  Patti Weber, National Institutes of Health
§  Adam Dole, Mayo Clinic
§  Jeffrey Schox, Schox Patent Group
§  Mike Holland, Kaiser Permanente
§  Jeffery Groom, University of Michigan
Medical Innovation Center
§  Veenu Aulakh, Center for Care
Innovation, Tides Foundation
THANK YOU!
§  Maria Ly, Skimble 
§  Borna Safabakhsh, Agile Diagnosis
§  Ryan Panchadsaram, Pipette
§  Rachel Kalmar, Senstore
§  Andrey Ostrovsky, Care at Hand
§  Michael Pan, Nephosity
§  Amy Sheng, CellScope
§  Sean Duffy, Omada Health
§  Brian Chiko, Cognitive Health Innovations
§  Jonathon Feit, Beyond Lucid
§  Shenly Glenn, New Company
§  Founding team, Reify Health
Thank you to the following people for their valuable insights:
A R O C K R E P O R T B Y

Contenu connexe

Tendances

Startup Roadmap Workshop
Startup Roadmap WorkshopStartup Roadmap Workshop
Startup Roadmap WorkshopMichael Skok
 
Y Combinator Startup Class #2 : Ideas, Products, Teams and Execution
Y Combinator Startup Class #2 : Ideas, Products, Teams and ExecutionY Combinator Startup Class #2 : Ideas, Products, Teams and Execution
Y Combinator Startup Class #2 : Ideas, Products, Teams and ExecutionFabien Grenet
 
The Invincible Company
The Invincible CompanyThe Invincible Company
The Invincible CompanyYves Pigneur
 
Scaling corporate ventures: the foundations.
Scaling corporate ventures: the foundations.Scaling corporate ventures: the foundations.
Scaling corporate ventures: the foundations.Bundl
 
Seedcamp Fund V Fundraising Deck
Seedcamp Fund V Fundraising DeckSeedcamp Fund V Fundraising Deck
Seedcamp Fund V Fundraising DeckSeedcamp
 
Steve Blank’s Petal Diagram vs. Rod King’s Value Engine Map: Visual Tools for...
Steve Blank’s Petal Diagram vs. Rod King’s Value Engine Map: Visual Tools for...Steve Blank’s Petal Diagram vs. Rod King’s Value Engine Map: Visual Tools for...
Steve Blank’s Petal Diagram vs. Rod King’s Value Engine Map: Visual Tools for...Rod King, Ph.D.
 
Launch your own: Corporate innovation accelerator
Launch your own: Corporate innovation acceleratorLaunch your own: Corporate innovation accelerator
Launch your own: Corporate innovation acceleratorBoard of Innovation
 
Startup Opportunity Discovery & Evaluation (SXSW)
Startup Opportunity Discovery & Evaluation (SXSW)Startup Opportunity Discovery & Evaluation (SXSW)
Startup Opportunity Discovery & Evaluation (SXSW)Neal Cabage
 
Y Combinator Startup Class #1 : Ideas, Products, Teams and Execution (Part 1)
Y Combinator Startup Class #1 : Ideas, Products, Teams and Execution (Part 1)Y Combinator Startup Class #1 : Ideas, Products, Teams and Execution (Part 1)
Y Combinator Startup Class #1 : Ideas, Products, Teams and Execution (Part 1)Fabien Grenet
 
Understanding Venture Capital
Understanding Venture CapitalUnderstanding Venture Capital
Understanding Venture Capitalsimonolson
 
Go To Market – Case – Demandware Rebranding
Go To Market – Case – Demandware RebrandingGo To Market – Case – Demandware Rebranding
Go To Market – Case – Demandware RebrandingMichael Skok
 
AIPMM Phase Review Process for Product Management
AIPMM Phase Review Process for Product ManagementAIPMM Phase Review Process for Product Management
AIPMM Phase Review Process for Product ManagementAIPMM Administration
 
A Brief Overview of Strategic Foresight - Workshop Slides for SSE-O
A Brief Overview of Strategic Foresight - Workshop Slides for SSE-OA Brief Overview of Strategic Foresight - Workshop Slides for SSE-O
A Brief Overview of Strategic Foresight - Workshop Slides for SSE-OJosinaV
 
Crossing The Chasm
Crossing The ChasmCrossing The Chasm
Crossing The ChasmAndre Kearns
 
Product Market Fit - How to know your product is market fit
Product Market Fit - How to know your product is market fitProduct Market Fit - How to know your product is market fit
Product Market Fit - How to know your product is market fitSaif Hassan
 
Techstars Boston - The Secret Playbook of Raising $$$ - May 2022
Techstars Boston - The Secret Playbook of Raising $$$ - May 2022Techstars Boston - The Secret Playbook of Raising $$$ - May 2022
Techstars Boston - The Secret Playbook of Raising $$$ - May 2022David Chang
 
Startup funding : bootstrapping vs fundraising
Startup funding : bootstrapping vs fundraisingStartup funding : bootstrapping vs fundraising
Startup funding : bootstrapping vs fundraisingFrance Digitale
 

Tendances (20)

Startup Roadmap Workshop
Startup Roadmap WorkshopStartup Roadmap Workshop
Startup Roadmap Workshop
 
Y Combinator Startup Class #2 : Ideas, Products, Teams and Execution
Y Combinator Startup Class #2 : Ideas, Products, Teams and ExecutionY Combinator Startup Class #2 : Ideas, Products, Teams and Execution
Y Combinator Startup Class #2 : Ideas, Products, Teams and Execution
 
The Invincible Company
The Invincible CompanyThe Invincible Company
The Invincible Company
 
Scaling corporate ventures: the foundations.
Scaling corporate ventures: the foundations.Scaling corporate ventures: the foundations.
Scaling corporate ventures: the foundations.
 
Seedcamp Fund V Fundraising Deck
Seedcamp Fund V Fundraising DeckSeedcamp Fund V Fundraising Deck
Seedcamp Fund V Fundraising Deck
 
Steve Blank’s Petal Diagram vs. Rod King’s Value Engine Map: Visual Tools for...
Steve Blank’s Petal Diagram vs. Rod King’s Value Engine Map: Visual Tools for...Steve Blank’s Petal Diagram vs. Rod King’s Value Engine Map: Visual Tools for...
Steve Blank’s Petal Diagram vs. Rod King’s Value Engine Map: Visual Tools for...
 
Launch your own: Corporate innovation accelerator
Launch your own: Corporate innovation acceleratorLaunch your own: Corporate innovation accelerator
Launch your own: Corporate innovation accelerator
 
Startup Opportunity Discovery & Evaluation (SXSW)
Startup Opportunity Discovery & Evaluation (SXSW)Startup Opportunity Discovery & Evaluation (SXSW)
Startup Opportunity Discovery & Evaluation (SXSW)
 
Y Combinator Startup Class #1 : Ideas, Products, Teams and Execution (Part 1)
Y Combinator Startup Class #1 : Ideas, Products, Teams and Execution (Part 1)Y Combinator Startup Class #1 : Ideas, Products, Teams and Execution (Part 1)
Y Combinator Startup Class #1 : Ideas, Products, Teams and Execution (Part 1)
 
Understanding Venture Capital
Understanding Venture CapitalUnderstanding Venture Capital
Understanding Venture Capital
 
Go To Market – Case – Demandware Rebranding
Go To Market – Case – Demandware RebrandingGo To Market – Case – Demandware Rebranding
Go To Market – Case – Demandware Rebranding
 
Hypercompetition
HypercompetitionHypercompetition
Hypercompetition
 
Business Model
Business ModelBusiness Model
Business Model
 
How Square is Disrupting Banks
How Square is Disrupting BanksHow Square is Disrupting Banks
How Square is Disrupting Banks
 
AIPMM Phase Review Process for Product Management
AIPMM Phase Review Process for Product ManagementAIPMM Phase Review Process for Product Management
AIPMM Phase Review Process for Product Management
 
A Brief Overview of Strategic Foresight - Workshop Slides for SSE-O
A Brief Overview of Strategic Foresight - Workshop Slides for SSE-OA Brief Overview of Strategic Foresight - Workshop Slides for SSE-O
A Brief Overview of Strategic Foresight - Workshop Slides for SSE-O
 
Crossing The Chasm
Crossing The ChasmCrossing The Chasm
Crossing The Chasm
 
Product Market Fit - How to know your product is market fit
Product Market Fit - How to know your product is market fitProduct Market Fit - How to know your product is market fit
Product Market Fit - How to know your product is market fit
 
Techstars Boston - The Secret Playbook of Raising $$$ - May 2022
Techstars Boston - The Secret Playbook of Raising $$$ - May 2022Techstars Boston - The Secret Playbook of Raising $$$ - May 2022
Techstars Boston - The Secret Playbook of Raising $$$ - May 2022
 
Startup funding : bootstrapping vs fundraising
Startup funding : bootstrapping vs fundraisingStartup funding : bootstrapping vs fundraising
Startup funding : bootstrapping vs fundraising
 

En vedette

5 Trends Marketers Should Not Ignore
5 Trends Marketers Should Not Ignore5 Trends Marketers Should Not Ignore
5 Trends Marketers Should Not IgnoreEkaterina Walter
 
Bill 53 FD1
Bill 53 FD1Bill 53 FD1
Bill 53 FD1Burt Lum
 
Sample letter of intent
Sample letter of intentSample letter of intent
Sample letter of intentVishal Kumar
 
Five steps of startup go to-market
Five steps of startup go to-marketFive steps of startup go to-market
Five steps of startup go to-marketGuy Turner
 
Startup Metrics for Pirates
Startup Metrics for PiratesStartup Metrics for Pirates
Startup Metrics for PiratesDave McClure
 
Using Conversion Rate Optimisation and Viral Mechanics - Marcus Taylor
Using Conversion Rate Optimisation and Viral Mechanics - Marcus TaylorUsing Conversion Rate Optimisation and Viral Mechanics - Marcus Taylor
Using Conversion Rate Optimisation and Viral Mechanics - Marcus TaylorVenture Harbour
 
Q3 2012 Digital Health Funding Report by @Rock_Health
Q3 2012 Digital Health Funding Report by @Rock_HealthQ3 2012 Digital Health Funding Report by @Rock_Health
Q3 2012 Digital Health Funding Report by @Rock_HealthRock Health
 
Medical Device Regulations
Medical Device RegulationsMedical Device Regulations
Medical Device RegulationsLaura Faulconer
 
Rock Report: Fitness Technology for Athletes by @Rock_Health
Rock Report: Fitness Technology for Athletes by @Rock_HealthRock Report: Fitness Technology for Athletes by @Rock_Health
Rock Report: Fitness Technology for Athletes by @Rock_HealthRock Health
 
The Beginner’s Guide to Growth Hacking
The Beginner’s Guide to Growth HackingThe Beginner’s Guide to Growth Hacking
The Beginner’s Guide to Growth HackingFrederik Hermann
 
2013 Midyear Digital Health Funding by @Rock_Health
2013 Midyear Digital Health Funding by @Rock_Health2013 Midyear Digital Health Funding by @Rock_Health
2013 Midyear Digital Health Funding by @Rock_HealthRock Health
 
B2B B2C Marketing Strategies That Work for Both
B2B B2C Marketing Strategies That Work for BothB2B B2C Marketing Strategies That Work for Both
B2B B2C Marketing Strategies That Work for BothSilverpop
 
Strategic planning in laboratory industry
Strategic planning in laboratory industryStrategic planning in laboratory industry
Strategic planning in laboratory industryVarsha Shahane
 
B2B, B2C, B2B2C, marketplace: tutte le sfumature dell’eCommerce per creare va...
B2B, B2C, B2B2C, marketplace: tutte le sfumature dell’eCommerce per creare va...B2B, B2C, B2B2C, marketplace: tutte le sfumature dell’eCommerce per creare va...
B2B, B2C, B2B2C, marketplace: tutte le sfumature dell’eCommerce per creare va...Accenture Italia
 

En vedette (20)

5 Trends Marketers Should Not Ignore
5 Trends Marketers Should Not Ignore5 Trends Marketers Should Not Ignore
5 Trends Marketers Should Not Ignore
 
How to Use Reddit For Marketing
How to Use Reddit For MarketingHow to Use Reddit For Marketing
How to Use Reddit For Marketing
 
Bill 53 FD1
Bill 53 FD1Bill 53 FD1
Bill 53 FD1
 
Sample letter of intent
Sample letter of intentSample letter of intent
Sample letter of intent
 
Five steps of startup go to-market
Five steps of startup go to-marketFive steps of startup go to-market
Five steps of startup go to-market
 
How to Create Whiteboard videos
How to Create Whiteboard videosHow to Create Whiteboard videos
How to Create Whiteboard videos
 
Startup Metrics for Pirates
Startup Metrics for PiratesStartup Metrics for Pirates
Startup Metrics for Pirates
 
Evidence-Generation in Digital Healthcare: Demonstrating Value. Prakash Navar...
Evidence-Generation in Digital Healthcare: Demonstrating Value. Prakash Navar...Evidence-Generation in Digital Healthcare: Demonstrating Value. Prakash Navar...
Evidence-Generation in Digital Healthcare: Demonstrating Value. Prakash Navar...
 
Biobanks - Building the road to personalized medicine. Olli Carpen, Universit...
Biobanks - Building the road to personalized medicine. Olli Carpen, Universit...Biobanks - Building the road to personalized medicine. Olli Carpen, Universit...
Biobanks - Building the road to personalized medicine. Olli Carpen, Universit...
 
Using Conversion Rate Optimisation and Viral Mechanics - Marcus Taylor
Using Conversion Rate Optimisation and Viral Mechanics - Marcus TaylorUsing Conversion Rate Optimisation and Viral Mechanics - Marcus Taylor
Using Conversion Rate Optimisation and Viral Mechanics - Marcus Taylor
 
Q3 2012 Digital Health Funding Report by @Rock_Health
Q3 2012 Digital Health Funding Report by @Rock_HealthQ3 2012 Digital Health Funding Report by @Rock_Health
Q3 2012 Digital Health Funding Report by @Rock_Health
 
Open Door Forum: Next Generation ACO Model - Letter of Intent and Application
Open Door Forum: Next Generation ACO Model - Letter of Intent and ApplicationOpen Door Forum: Next Generation ACO Model - Letter of Intent and Application
Open Door Forum: Next Generation ACO Model - Letter of Intent and Application
 
Medical Device Regulations
Medical Device RegulationsMedical Device Regulations
Medical Device Regulations
 
Rock Report: Fitness Technology for Athletes by @Rock_Health
Rock Report: Fitness Technology for Athletes by @Rock_HealthRock Report: Fitness Technology for Athletes by @Rock_Health
Rock Report: Fitness Technology for Athletes by @Rock_Health
 
The Beginner’s Guide to Growth Hacking
The Beginner’s Guide to Growth HackingThe Beginner’s Guide to Growth Hacking
The Beginner’s Guide to Growth Hacking
 
2013 Midyear Digital Health Funding by @Rock_Health
2013 Midyear Digital Health Funding by @Rock_Health2013 Midyear Digital Health Funding by @Rock_Health
2013 Midyear Digital Health Funding by @Rock_Health
 
B2B B2C Marketing Strategies That Work for Both
B2B B2C Marketing Strategies That Work for BothB2B B2C Marketing Strategies That Work for Both
B2B B2C Marketing Strategies That Work for Both
 
Program Digital Health: bringing together payers & pitches. Ulli Jendrik Koop...
Program Digital Health: bringing together payers & pitches. Ulli Jendrik Koop...Program Digital Health: bringing together payers & pitches. Ulli Jendrik Koop...
Program Digital Health: bringing together payers & pitches. Ulli Jendrik Koop...
 
Strategic planning in laboratory industry
Strategic planning in laboratory industryStrategic planning in laboratory industry
Strategic planning in laboratory industry
 
B2B, B2C, B2B2C, marketplace: tutte le sfumature dell’eCommerce per creare va...
B2B, B2C, B2B2C, marketplace: tutte le sfumature dell’eCommerce per creare va...B2B, B2C, B2B2C, marketplace: tutte le sfumature dell’eCommerce per creare va...
B2B, B2C, B2B2C, marketplace: tutte le sfumature dell’eCommerce per creare va...
 

Similaire à The Entrepreneur's Guide to Hospital Partnerships by @Rock_Health

Aagami Inc. Company Presentation
Aagami Inc. Company PresentationAagami Inc. Company Presentation
Aagami Inc. Company PresentationGodwyn Francis
 
biotech bulletin-2015-spring
biotech bulletin-2015-springbiotech bulletin-2015-spring
biotech bulletin-2015-springBrian Filippini
 
Karson approaching innovation with commercial ehrs
Karson approaching innovation with commercial ehrsKarson approaching innovation with commercial ehrs
Karson approaching innovation with commercial ehrsTrimed Media Group
 
Converge Advisory Group
Converge Advisory GroupConverge Advisory Group
Converge Advisory GroupRobert Liebman
 
Ey beyondborders: unlocking value
Ey beyondborders: unlocking valueEy beyondborders: unlocking value
Ey beyondborders: unlocking valueFrédéric Barillet
 
Strategies for Conducting New Product Scientific Assessment - Yavuz SILAY - D...
Strategies for Conducting New Product Scientific Assessment - Yavuz SILAY - D...Strategies for Conducting New Product Scientific Assessment - Yavuz SILAY - D...
Strategies for Conducting New Product Scientific Assessment - Yavuz SILAY - D...Yavuz Silay
 
International Pharmaceutical Industry: Feasibility Is Not (Anymore) A Plain S...
International Pharmaceutical Industry: Feasibility Is Not (Anymore) A Plain S...International Pharmaceutical Industry: Feasibility Is Not (Anymore) A Plain S...
International Pharmaceutical Industry: Feasibility Is Not (Anymore) A Plain S...KCR
 
OneStart 2015 London Bootcamp: Ilan Zipkin, Takeda Ventures - Development Pat...
OneStart 2015 London Bootcamp: Ilan Zipkin, Takeda Ventures - Development Pat...OneStart 2015 London Bootcamp: Ilan Zipkin, Takeda Ventures - Development Pat...
OneStart 2015 London Bootcamp: Ilan Zipkin, Takeda Ventures - Development Pat...Oxbridge Biotech Roundtable
 
Justin Graham, Chief Innovation Officer, HEARST
Justin Graham, Chief Innovation Officer, HEARSTJustin Graham, Chief Innovation Officer, HEARST
Justin Graham, Chief Innovation Officer, HEARSTWorld_Forum_Disrupt
 
Integrate RWE into clinical development
Integrate RWE into clinical developmentIntegrate RWE into clinical development
Integrate RWE into clinical developmentIMSHealthRWES
 
Avoca Quality Consortium 2014 Summit Bio Booklet
Avoca Quality Consortium 2014 Summit Bio BookletAvoca Quality Consortium 2014 Summit Bio Booklet
Avoca Quality Consortium 2014 Summit Bio BookletThe Avoca Group
 
Biotech Bulletin - Summer 2015
Biotech Bulletin - Summer 2015Biotech Bulletin - Summer 2015
Biotech Bulletin - Summer 2015Regina M Maxwell
 
Highlights from ExL Pharma's 4th Latin America Clinical Trials
Highlights from  ExL Pharma's 4th Latin America Clinical TrialsHighlights from  ExL Pharma's 4th Latin America Clinical Trials
Highlights from ExL Pharma's 4th Latin America Clinical TrialsExL Pharma
 
Excel in Health: Proposition
Excel in Health: PropositionExcel in Health: Proposition
Excel in Health: PropositionInnovation Agency
 
Quantifying & Capturing Value In the Age of Healthcare Reform
Quantifying & Capturing Value In the Age of Healthcare ReformQuantifying & Capturing Value In the Age of Healthcare Reform
Quantifying & Capturing Value In the Age of Healthcare ReformLeveragePoint Innovations
 
Introduction to the TSRL, Inc. Accelerator Model
Introduction to the TSRL, Inc. Accelerator ModelIntroduction to the TSRL, Inc. Accelerator Model
Introduction to the TSRL, Inc. Accelerator ModelDrew Hertig, MBA, CLP
 
Huntingtin Ingalls- Newport News Shipbuilding Mission - Value.docx
Huntingtin Ingalls- Newport News Shipbuilding Mission - Value.docxHuntingtin Ingalls- Newport News Shipbuilding Mission - Value.docx
Huntingtin Ingalls- Newport News Shipbuilding Mission - Value.docxsheronlewthwaite
 

Similaire à The Entrepreneur's Guide to Hospital Partnerships by @Rock_Health (20)

Aagami Inc. Company Presentation
Aagami Inc. Company PresentationAagami Inc. Company Presentation
Aagami Inc. Company Presentation
 
biotech bulletin-2015-spring
biotech bulletin-2015-springbiotech bulletin-2015-spring
biotech bulletin-2015-spring
 
Biotech Bulletin 2Q2015
Biotech Bulletin 2Q2015Biotech Bulletin 2Q2015
Biotech Bulletin 2Q2015
 
Karson approaching innovation with commercial ehrs
Karson approaching innovation with commercial ehrsKarson approaching innovation with commercial ehrs
Karson approaching innovation with commercial ehrs
 
Converge Advisory Group
Converge Advisory GroupConverge Advisory Group
Converge Advisory Group
 
pc15147_brochure
pc15147_brochurepc15147_brochure
pc15147_brochure
 
Ey beyondborders: unlocking value
Ey beyondborders: unlocking valueEy beyondborders: unlocking value
Ey beyondborders: unlocking value
 
Strategies for Conducting New Product Scientific Assessment - Yavuz SILAY - D...
Strategies for Conducting New Product Scientific Assessment - Yavuz SILAY - D...Strategies for Conducting New Product Scientific Assessment - Yavuz SILAY - D...
Strategies for Conducting New Product Scientific Assessment - Yavuz SILAY - D...
 
International Pharmaceutical Industry: Feasibility Is Not (Anymore) A Plain S...
International Pharmaceutical Industry: Feasibility Is Not (Anymore) A Plain S...International Pharmaceutical Industry: Feasibility Is Not (Anymore) A Plain S...
International Pharmaceutical Industry: Feasibility Is Not (Anymore) A Plain S...
 
OneStart 2015 London Bootcamp: Ilan Zipkin, Takeda Ventures - Development Pat...
OneStart 2015 London Bootcamp: Ilan Zipkin, Takeda Ventures - Development Pat...OneStart 2015 London Bootcamp: Ilan Zipkin, Takeda Ventures - Development Pat...
OneStart 2015 London Bootcamp: Ilan Zipkin, Takeda Ventures - Development Pat...
 
CIMIT (Boston) Presentation | CRAASH Barcelona
CIMIT (Boston) Presentation | CRAASH BarcelonaCIMIT (Boston) Presentation | CRAASH Barcelona
CIMIT (Boston) Presentation | CRAASH Barcelona
 
Justin Graham, Chief Innovation Officer, HEARST
Justin Graham, Chief Innovation Officer, HEARSTJustin Graham, Chief Innovation Officer, HEARST
Justin Graham, Chief Innovation Officer, HEARST
 
Integrate RWE into clinical development
Integrate RWE into clinical developmentIntegrate RWE into clinical development
Integrate RWE into clinical development
 
Avoca Quality Consortium 2014 Summit Bio Booklet
Avoca Quality Consortium 2014 Summit Bio BookletAvoca Quality Consortium 2014 Summit Bio Booklet
Avoca Quality Consortium 2014 Summit Bio Booklet
 
Biotech Bulletin - Summer 2015
Biotech Bulletin - Summer 2015Biotech Bulletin - Summer 2015
Biotech Bulletin - Summer 2015
 
Highlights from ExL Pharma's 4th Latin America Clinical Trials
Highlights from  ExL Pharma's 4th Latin America Clinical TrialsHighlights from  ExL Pharma's 4th Latin America Clinical Trials
Highlights from ExL Pharma's 4th Latin America Clinical Trials
 
Excel in Health: Proposition
Excel in Health: PropositionExcel in Health: Proposition
Excel in Health: Proposition
 
Quantifying & Capturing Value In the Age of Healthcare Reform
Quantifying & Capturing Value In the Age of Healthcare ReformQuantifying & Capturing Value In the Age of Healthcare Reform
Quantifying & Capturing Value In the Age of Healthcare Reform
 
Introduction to the TSRL, Inc. Accelerator Model
Introduction to the TSRL, Inc. Accelerator ModelIntroduction to the TSRL, Inc. Accelerator Model
Introduction to the TSRL, Inc. Accelerator Model
 
Huntingtin Ingalls- Newport News Shipbuilding Mission - Value.docx
Huntingtin Ingalls- Newport News Shipbuilding Mission - Value.docxHuntingtin Ingalls- Newport News Shipbuilding Mission - Value.docx
Huntingtin Ingalls- Newport News Shipbuilding Mission - Value.docx
 

Plus de Rock Health

The State of Women in Healthcare 2015 by @Rock_Health
The State of Women in Healthcare 2015 by @Rock_HealthThe State of Women in Healthcare 2015 by @Rock_Health
The State of Women in Healthcare 2015 by @Rock_HealthRock Health
 
The Future of Personalized Health Care: Predictive Analytics by @Rock_Health
The Future of Personalized Health Care: Predictive Analytics by @Rock_HealthThe Future of Personalized Health Care: Predictive Analytics by @Rock_Health
The Future of Personalized Health Care: Predictive Analytics by @Rock_HealthRock Health
 
Digital Health Funding 2014 Midyear Report by @Rock_Health
Digital Health Funding 2014 Midyear Report by @Rock_HealthDigital Health Funding 2014 Midyear Report by @Rock_Health
Digital Health Funding 2014 Midyear Report by @Rock_HealthRock Health
 
The Future of Biosensing Wearables by @Rock_Health
The Future of Biosensing Wearables by @Rock_HealthThe Future of Biosensing Wearables by @Rock_Health
The Future of Biosensing Wearables by @Rock_HealthRock Health
 
Digital Health Funding 2013 Year in Review by @Rock_Health
Digital Health Funding 2013 Year in Review by @Rock_HealthDigital Health Funding 2013 Year in Review by @Rock_Health
Digital Health Funding 2013 Year in Review by @Rock_HealthRock Health
 
Rock Report: Smart Seating - Opportunities at the intersection of automotive ...
Rock Report: Smart Seating - Opportunities at the intersection of automotive ...Rock Report: Smart Seating - Opportunities at the intersection of automotive ...
Rock Report: Smart Seating - Opportunities at the intersection of automotive ...Rock Health
 
Rock Report: Big Data by @Rock_Health
Rock Report: Big Data by @Rock_HealthRock Report: Big Data by @Rock_Health
Rock Report: Big Data by @Rock_HealthRock Health
 
Rock Report: Personalization in Consumer Health by @Rock_Health
Rock Report: Personalization in Consumer Health by @Rock_HealthRock Report: Personalization in Consumer Health by @Rock_Health
Rock Report: Personalization in Consumer Health by @Rock_HealthRock Health
 
Women in Healthcare by @Rock_Health
Women in Healthcare by @Rock_HealthWomen in Healthcare by @Rock_Health
Women in Healthcare by @Rock_HealthRock Health
 
Rock Report: Sensors by @Rock_Health
Rock Report: Sensors by @Rock_HealthRock Report: Sensors by @Rock_Health
Rock Report: Sensors by @Rock_HealthRock Health
 

Plus de Rock Health (10)

The State of Women in Healthcare 2015 by @Rock_Health
The State of Women in Healthcare 2015 by @Rock_HealthThe State of Women in Healthcare 2015 by @Rock_Health
The State of Women in Healthcare 2015 by @Rock_Health
 
The Future of Personalized Health Care: Predictive Analytics by @Rock_Health
The Future of Personalized Health Care: Predictive Analytics by @Rock_HealthThe Future of Personalized Health Care: Predictive Analytics by @Rock_Health
The Future of Personalized Health Care: Predictive Analytics by @Rock_Health
 
Digital Health Funding 2014 Midyear Report by @Rock_Health
Digital Health Funding 2014 Midyear Report by @Rock_HealthDigital Health Funding 2014 Midyear Report by @Rock_Health
Digital Health Funding 2014 Midyear Report by @Rock_Health
 
The Future of Biosensing Wearables by @Rock_Health
The Future of Biosensing Wearables by @Rock_HealthThe Future of Biosensing Wearables by @Rock_Health
The Future of Biosensing Wearables by @Rock_Health
 
Digital Health Funding 2013 Year in Review by @Rock_Health
Digital Health Funding 2013 Year in Review by @Rock_HealthDigital Health Funding 2013 Year in Review by @Rock_Health
Digital Health Funding 2013 Year in Review by @Rock_Health
 
Rock Report: Smart Seating - Opportunities at the intersection of automotive ...
Rock Report: Smart Seating - Opportunities at the intersection of automotive ...Rock Report: Smart Seating - Opportunities at the intersection of automotive ...
Rock Report: Smart Seating - Opportunities at the intersection of automotive ...
 
Rock Report: Big Data by @Rock_Health
Rock Report: Big Data by @Rock_HealthRock Report: Big Data by @Rock_Health
Rock Report: Big Data by @Rock_Health
 
Rock Report: Personalization in Consumer Health by @Rock_Health
Rock Report: Personalization in Consumer Health by @Rock_HealthRock Report: Personalization in Consumer Health by @Rock_Health
Rock Report: Personalization in Consumer Health by @Rock_Health
 
Women in Healthcare by @Rock_Health
Women in Healthcare by @Rock_HealthWomen in Healthcare by @Rock_Health
Women in Healthcare by @Rock_Health
 
Rock Report: Sensors by @Rock_Health
Rock Report: Sensors by @Rock_HealthRock Report: Sensors by @Rock_Health
Rock Report: Sensors by @Rock_Health
 

Dernier

Apiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptApiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptkedirjemalharun
 
Nutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience ClassNutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience Classmanuelazg2001
 
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara RajendranMusic Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara RajendranTara Rajendran
 
Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.Prerana Jadhav
 
Valproic Acid. (VPA). Antiseizure medication
Valproic Acid.  (VPA). Antiseizure medicationValproic Acid.  (VPA). Antiseizure medication
Valproic Acid. (VPA). Antiseizure medicationMohamadAlhes
 
L1.INTRODUCTION to ENDOCRINOLOGY MEDICINE.pptx
L1.INTRODUCTION to ENDOCRINOLOGY MEDICINE.pptxL1.INTRODUCTION to ENDOCRINOLOGY MEDICINE.pptx
L1.INTRODUCTION to ENDOCRINOLOGY MEDICINE.pptxDr Bilal Natiq
 
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdfLippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdfSreeja Cherukuru
 
Phytochemical Investigation of Drugs PDF.pdf
Phytochemical Investigation of Drugs PDF.pdfPhytochemical Investigation of Drugs PDF.pdf
Phytochemical Investigation of Drugs PDF.pdfDivya Kanojiya
 
Plant Fibres used as Surgical Dressings PDF.pdf
Plant Fibres used as Surgical Dressings PDF.pdfPlant Fibres used as Surgical Dressings PDF.pdf
Plant Fibres used as Surgical Dressings PDF.pdfDivya Kanojiya
 
PNEUMOTHORAX AND ITS MANAGEMENTS.pdf
PNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdfPNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdf
PNEUMOTHORAX AND ITS MANAGEMENTS.pdfDolisha Warbi
 
SHOCK (Medical SURGICAL BASED EDITION)).pptx
SHOCK (Medical SURGICAL BASED EDITION)).pptxSHOCK (Medical SURGICAL BASED EDITION)).pptx
SHOCK (Medical SURGICAL BASED EDITION)).pptxAbhishek943418
 
Culture and Health Disorders Social change.pptx
Culture and Health Disorders Social change.pptxCulture and Health Disorders Social change.pptx
Culture and Health Disorders Social change.pptxDr. Dheeraj Kumar
 
Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)
Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)
Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)MohamadAlhes
 
Introduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiIntroduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiGoogle
 
History and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfHistory and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfSasikiranMarri
 
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
COVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptxCOVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptx
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptxBibekananda shah
 
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptxSYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptxdrashraf369
 
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...sdateam0
 
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaurMETHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaurNavdeep Kaur
 
CCSC6142 Week 3 Research ethics - Long Hoang.pdf
CCSC6142 Week 3 Research ethics - Long Hoang.pdfCCSC6142 Week 3 Research ethics - Long Hoang.pdf
CCSC6142 Week 3 Research ethics - Long Hoang.pdfMyThaoAiDoan
 

Dernier (20)

Apiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptApiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.ppt
 
Nutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience ClassNutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience Class
 
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara RajendranMusic Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
 
Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.
 
Valproic Acid. (VPA). Antiseizure medication
Valproic Acid.  (VPA). Antiseizure medicationValproic Acid.  (VPA). Antiseizure medication
Valproic Acid. (VPA). Antiseizure medication
 
L1.INTRODUCTION to ENDOCRINOLOGY MEDICINE.pptx
L1.INTRODUCTION to ENDOCRINOLOGY MEDICINE.pptxL1.INTRODUCTION to ENDOCRINOLOGY MEDICINE.pptx
L1.INTRODUCTION to ENDOCRINOLOGY MEDICINE.pptx
 
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdfLippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
 
Phytochemical Investigation of Drugs PDF.pdf
Phytochemical Investigation of Drugs PDF.pdfPhytochemical Investigation of Drugs PDF.pdf
Phytochemical Investigation of Drugs PDF.pdf
 
Plant Fibres used as Surgical Dressings PDF.pdf
Plant Fibres used as Surgical Dressings PDF.pdfPlant Fibres used as Surgical Dressings PDF.pdf
Plant Fibres used as Surgical Dressings PDF.pdf
 
PNEUMOTHORAX AND ITS MANAGEMENTS.pdf
PNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdfPNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdf
PNEUMOTHORAX AND ITS MANAGEMENTS.pdf
 
SHOCK (Medical SURGICAL BASED EDITION)).pptx
SHOCK (Medical SURGICAL BASED EDITION)).pptxSHOCK (Medical SURGICAL BASED EDITION)).pptx
SHOCK (Medical SURGICAL BASED EDITION)).pptx
 
Culture and Health Disorders Social change.pptx
Culture and Health Disorders Social change.pptxCulture and Health Disorders Social change.pptx
Culture and Health Disorders Social change.pptx
 
Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)
Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)
Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)
 
Introduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiIntroduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali Rai
 
History and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfHistory and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdf
 
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
COVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptxCOVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptx
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
 
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptxSYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
 
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
 
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaurMETHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
 
CCSC6142 Week 3 Research ethics - Long Hoang.pdf
CCSC6142 Week 3 Research ethics - Long Hoang.pdfCCSC6142 Week 3 Research ethics - Long Hoang.pdf
CCSC6142 Week 3 Research ethics - Long Hoang.pdf
 

The Entrepreneur's Guide to Hospital Partnerships by @Rock_Health

  • 1. A R O C K R E P O R T B Y THE ENTREPRENEUR’S GUIDE ! TO HOSPITAL PARTNERSHIPS A R O C K R E P O R T B Y
  • 2. This document should serve as a guide for entrepreneurs as they navigate partnering with health care providers. This first draft was compiled after 22 interviews with entrepreneurs, hospital administrators, investors, lawyers, clinicians and researchers. This is a living document, intended to grow and improve with your input. Authors: •  Sasha Buscho, Harvard MPH •  Christina Chang, Harvard MBA •  Aenor Sawyer, MD, UCSF Clinician Editor •  Halle Tecco, Rock Health CEO •  Malay Gandhi, Rock Health Mentor-in-Residence •  Adam Dole, Mayo Clinic About this Guide ROCK HEALTH is powering the future of the digital health ecosystem, bringing together the brightest minds across disciplines to build better solutions. Rock Health funds and supports startups building the next generation of technologies transforming healthcare. ROCK HEALTH partners include Alexandria Real Estate Equities, Boehringer Ingelheim, Fenwick & West, GE, Genentech, Harvard Medical School, Kaiser Permanente, Kleiner Perkins Caufield & Byers, Mayo Clinic, Mohr Davidow Ventures, Montreux Equity Partners, NEA, Ogilvy Public Relations, Qualcomm Life and UCSF. LEARN MORE AT rockhealth.com
  • 3. How can startups and health care providers partner more effectively to pilot and commercialize digital health innovations? A R O C K R E P O R T B Y
  • 4. BACKGROUND Scope of Guidelines The goal of the pilot is two fold: validation and progression to full- scale commercialization The digital healthcare pilot is defined as a product implementation trial with end-users / potential customers Definition Goal A R O C K R E P O R T B Y
  • 5. KEY CHALLENGES Divergent Risk Profiles Health care providers have many priorities including health outcomes, patient safety and security and best practices research. Startups prioritize new practices, adoption and growth A R O C K R E P O R T B Y
  • 6. KEY CHALLENGES Divergent Risk Profiles Differing Motivations Health care providers have many priorities including health outcomes, patient safety and security and best practices research. Startups prioritize new practices, adoption and growth Some “motivators” for provider participation, including shared intellectual property, equity, and key metrics, may not align with startup goals A R O C K R E P O R T B Y
  • 7. KEY CHALLENGES Divergent Risk Profiles Differing Motivations Distinct Cultures Startups and providers have significant differences in availability, team size, decision-making dynamics, and overall timelines Health care providers have many priorities including health outcomes, patient safety and security and best practices research. Startups prioritize new practices, adoption and growth Some “motivators” for provider participation, including shared intellectual property, equity, and key metrics, may not align with startup goals A R O C K R E P O R T B Y
  • 8. KEY CHALLENGES Divergent Risk Profiles Differing Motivations Some “motivators” for provider participation, including shared intellectual property, equity, and key metrics, may not align with startup goals Distinct Cultures Startups and providers have significant differences in availability, team size, decision-making dynamics, and overall timelines Complex Regulations Institutions enforce a multitude of regulations, both internal (e.g. IRB) and external (e.g. FDA), which are difficult to interpret without internal champions Health care providers have many priorities including health outcomes, patient safety and security and best practices research. Startups prioritize new practices, adoption and growth A R O C K R E P O R T B Y
  • 9. Deployment Strategy: Pushing a product or service to the patient for testing is different than getting hospitals or clinicians to adopt and distribute technologies themselves KEY CONSIDERATION: Consumer-Facing VS. Enterprise Solutions Purpose: Pilots for B2B startups are needed to demonstrate outcomes that motivate enterprise buyers while B2C startups can gain significant brand recognition from validation within a provider setting A R O C K R E P O R T B Y
  • 10. Hospitals have many established systems that if leveraged properly, can represent significant distribution channels for new technologies. Whether you’re a B2B or B2C, it is important to consider how a startup’s product or service could be integrated into the existing hospital systems. - Adam Dole, Mayo Clinic A R O C K R E P O R T B Y
  • 11. KEY CONSIDERATION: A device startup likely follows a rigorous timeline, runs pilots that require IRB/human subjects approval, patenting, publishing, FDA clearance and approval Medical Devices VS. Digital Health A digital health startup may be eligible for an expedited or exempt IRB and less-rigorous regulatory process. BUT they may also have a harder time connecting with a provider, due to difficulties such as clinician workflow integration, difficult to measure outcomes, IT infrastructure issues and misaligned incentives A R O C K R E P O R T B Y
  • 12. Clinical evaluation focuses on product usability, adoption and/or impact. This can require rigorous scientific methods and often a longer, more intimate relationship with the hospital partner Business evaluation measures how the market values a company’s products and services. This requires clear negotiations upfront around the hurdles and milestones necessary to move from pilot to commercialization Clinical Efficacy VS. Business Model Evaluation KEY CONSIDERATION: A pilot should test both the clinical efficacy and business model of the product or service. But these tests can be quite different: A R O C K R E P O R T B Y
  • 14. LAUNCH customer building BUILD validation SCALE growth MATURE sustainability CONTEXT     I. Pre-Pilot II. Pilot Design III. Iteration   IV. Validation   startup lifecycle 4 PHASES 4-8 weeks 2-4 months 3-6 months ongoing pilot start 6-12 months for large scale testing A R O C K R E P O R T B Y
  • 15. PHASE 1: PRE-PILOT The startup has to involve clinical guidance early and often, starting from the early brainstorming portion. From experience – we will have startups that focus so much on the tech-side, then come to the frontlines to test it, and we realize it’s a mismatch for the problem. -- Aenor Sawyer, UCSF
  • 16. I. Pre-Pilot II. Pilot Design III. Iteration   IV. Validation   Clearly define what unmet need startup is looking to impact. Target Appropriate Hospital System (teaching hospital, a general hospital, a specialty hospital, or a clinic) §  Consider the goals of your pilot §  Does the payment system (pay-for performance vs. fee-for-service) matter? Understand how decisions are made, and who makes them §  How is the leadership structured? §  Who needs to be on-board to approve decisions? Find a Champion §  Network in your field, and find the right person(s) for your partnership. Discuss their interests, availability and commitments §  Champions are typically found through personal contacts or literature searches for researchers working on a related topic Complete HIPAA training, IRB / research training and scope out relevant FDA regulations File for a provisional patent Decide if the hospital partner will be an inventor-contributor or a data collector A R O C K R E P O R T B Y
  • 17. The pilot successes we've had happened when we did all of the legwork for our internal champion upfront—preparing for the IRB, designing a sufficiently powerful study—versus trying to figure out ways around it. - Joseph Abrahamson, CTO of Reify Health
  • 18. Collaboration in healthcare often leads to co-ownership of the patents, which sounds great but will scare off investors (since the hospital can license your competitor). One solution is to file a provisional patent application before starting the collaboration. -Jeffrey Schox, Startup Patent Lawyer
  • 19. PHASE 2: PILOT DESIGN The start-up needs to figure out who their customer is, and what evidence they need to sell to those customers. Digital healthcare startups can generally be classified as adding value to the healthcare system either on the delivery or administration side. Pilots for administrative startups need to create a business case about improving bottom-line performance of the health care provider, e.g. higher productivity, lowered costs, improved revenue or cash flow. Startups focused in the delivery side require comparison data on integration, usability and clinical outcomes. Here – depth of rigor and scientific analysis are critical. A randomized-control trial is not always feasible, but generally considered the gold standard for reliable clinical evidence. A R O C K R E P O R T B Y
  • 20. Pre-Pilot Pilot Design Iteration   Validation   Determine: Roles, scope, incentives §  Incentives for hospital involvement can include: publishing rights, equity, revenue- share, licensing, training opportunities for clinicians on mHealth §  Collaborate with partners to outline how much time is required by individuals from both groups…get specific. §  Clearly define the relationship. Is this a pilot? Partnership? Advisory position? Design Study §  Define the purpose of the study, and the appropriate research methods for that purpose. The pilot should be designed to directly test hypotheses. What is your study design (e.g. RCT, observational)? Set goals and metrics §  Measure the right processes and outcomes to test your driving hypotheses. Substantiate a case for moving from pilot to full-scale commercialization. Create timelines Complete institutional regulatory forms §  Including: IT Security Compliance / Confidentiality Agreement / IRB Approval / HIPAA certification Determine disclosure policies §  If you’re not ready to “go public” with the product, prepare an NDA Set budget and formalize all cost-sharing
  • 21. What can really take a long time inside of a healthcare institution, is coordinating the terms of the relationship and structuring the agreement. Every time a decision needs to be made many stakeholders need to be consulted. The more proactive and insightful a startup can be about what they want to get out of their relationship with the clinical partner the faster the relationship can move. - Adam Dole, Mayo Clinic
  • 22. The biggest challenge we faced was scheduling time with the clinicians. We really depended on our internal champion to stay enthusiastic and engaged, and to share the product with his colleagues. - Michael Pan, Nephosity
  • 23. PHASE 3: ITERATION During Phase 3, the initial small-scale roll out grows. Feedback and input on the product are discussed and incorporated. Evidence accumulates. The evolving product is tested in larger populations.
  • 24. Pre-Pilot Pilot Design Iteration   Validation   Relationship management: §  Once the pilot launches, the partners need to monitor and analyze data together, which involves regular communication §  Consider how the hospital staff is interacting with your technology, and adjust pain- points to facilitate ease of use Stage expansion plans §  Set check-points as the pilot grows. How many people will be included in the pilot? When will they be contacted? How many times will you iterate? §  Note that iterations may require further IRB and regulatory approvals Data analysis §  The pilot should test hypotheses you have already formed. Know who will lead the data analysis, and set a schedule to check results File for a patent §  The patent application should be filed within 12 months of the provisional Acquire appropriate funding to fuel growth A R O C K R E P O R T B Y
  • 25. PHASE 4: VALIDATION The startup should have sufficient evidence to sell to their customers, allowing the pilot to transform into full-scale commercialization “Sufficient evidence” can take many forms, depending on the pilot design (see Phase 2) Administrative pilots will find useful validation metrics in the changes in bottom-line performance of the hospital, provider usage, and user satisfaction Clinical pilots will find validation through rigorous and repeatable scientific research. Publication in a peer-reviewed journal is one reliable validation of clinical studies A R O C K R E P O R T B Y
  • 26. Pre-Pilot Pilot Design Iteration   Validation   Finalize validation criteria specific to your product or service Draft and publish a final report §  Who will be included as authors? §  How will the relationship be described? §  Which results are included in the report? §  Who is the target audience for the publication? File for FDA approval if product claims to treat or diagnose §  Inform FDA at least 90 days in advance of marketing a medical device A final report allows you to stick a flag in your research. If it’s truly novel and successful then it's going to cause a splash when it's published and your team should be prepared for that. Understand that research papers are important components of the domino effect. – Reify Health A R O C K R E P O R T B Y
  • 27. §  Target appropriate hospital system §  Study hospital structure/processes §  Find a champion §  Conduct research §  Determine: purpose, roles, scope, incentives §  Set goals and metrics §  Create timelines §  User recruitment §  Sign: BAA, Letter of Intent §  Staging expansion plans §  Data analysis §  Final Report Relationship Management §  HIPAA training §  IRB training §  FDA scoping §  Conflict of interests §  IT Security Compliance §  Confidentiality Agreement §  IRB Approval §  HIPAA certification •  Text •  •  Privacy/ Regulatory §  File provisional patent application §  Consider disclosure policies (NDA if necessary) §  File for patent (within 12 mos) Legal §  Seed funding §  Grant Application §  Budget §  Budget with hospitals §  Cost-sharing if applicable §  Acquire appropriate funds Fund- raising KEY Startup Startup / Provider collaboration SUMMARY Pre-Pilot Pilot Design Iteration   Validation   §  File for FDA clearance if applicable
  • 28. Stories from the trenches Product development and pilot testing can take many forms. Below are some creative ways entrepreneurs have hacked the system... Before we invested time and resources in a pilot, we recruited users on Craigslist to test our products and give us feedback. Once the product was developed and tested, we took it to the hospitals. We just gave the doctors iPads, and in return they agreed to give us feedback. We got the pilot running at that hospital in two weeks... Researchers at Mass General were interested in running these trials and publishing the results, because we were taking a proven scientific mechanism, and applying it to digital health. It could have major scientific implications. A R O C K R E P O R T B Y
  • 29. §  Find a champion: CEO utilized his network, connected with an interested psychologist at HMS / Mass Gen. §  Researcher incentives: career advancement, publishing §  Survey design: pre/post test §  Timelines, scope and roles set, BAA discussed §  Users recruited from clinic §  Expansion: second pilot with randomized control trial §  Data analysis and first publication led by PI §  First paper to be published in peer- reviewed journal Relationship Management §  HIPAA: made product and data anonymous §  IRB: used previously successful proposal §  Conflict of interest: Researcher opted-out of medical advisory & stock options §  IT Security Compliance approved §  Confidentiality Agreement: Drafted between hospital and patients, data stored anonymously §  IRB Approval: Takes 1.5 months Privacy/ Regulatory §  Grant Application: Jointly filed, with researcher as PI and startup CEO as “advisor” §  Received grant to cover research costs Fund- raising KEY Pre-Pilot Pilot Design Iteration   Validation   A Successful Partnership: Cognitive Health Innovations & Harvard Medical System §  Received second grant for a 3rd trial §  Patent not currently in process Legal A R O C K R E P O R T B Y
  • 30. APPENDIX A R O C K R E P O R T B Y
  • 31. Purpose §  What is the purpose of the partnership / pilot? §  What user needs does this product fulfill? §  What are you trying to validate with this partnership / pilot? Scope §  What is the expected timeline for this pilot / partnership? §  How will this project be funded? §  What specific actions / access / deliverables do you need from the health care provider? (Specify practice area / specialty, content, clinical protocol, etc.) §  What types of specialists or sub-specialists will be needed? What part of the technology will the specialists evaluate? Roles §  Who are the members of the startup and provider teams, and what are their specific roles (teach, train, data collection etc.)? Before approaching a hospital, prepare answers the questions below. Consider this a collaborative process and working document. DO YOUR HOMEWORK A R O C K R E P O R T B Y
  • 32. Roles (cont) §  How will each stakeholder benefit from this pilot? §  How will the startup describe their relationship with the provider to external parties? Is this a “partnership?” A “pilot?” A “co-investigation?” Incentives: §  Why should the provider invest time and resources in this? Will they benefit in terms of physical content (articles, etc), specific clinical protocols, advisory roles, etc.? §  How, specifically, can the provider add strategic value to this product? §  What, if any, advisory role will the provider play? §  What patents does the startup have that would attract the health care provider? (Remember to discuss patent and IP rights early) §  What benefits will the hospital receive? (equity, revenue share, licensing, etc) §  Is there a transition where the provider / customers will start to pay for the product? When? Will the pilot providers get a deal? §  Who will have access to the data? Who can publish the data? DO YOUR HOMEWORK (cont) A R O C K R E P O R T B Y
  • 33. §  Business Associates Agreement §  Proposal of Scope Examples §  IT Security Compliance Checklist §  HIPAA Compliance Checklist §  Confidentiality Agreement §  Non-Disclosure Agreement §  IRB Process and Guideline Examples rockhealth.com/resources RESOURCES A R O C K R E P O R T B Y
  • 34. §  Darren Hite, Aberdare Ventures §  Aman Bhandari, Health and Human Services §  Greg Downing, Health and Human Services §  Patti Weber, National Institutes of Health §  Adam Dole, Mayo Clinic §  Jeffrey Schox, Schox Patent Group §  Mike Holland, Kaiser Permanente §  Jeffery Groom, University of Michigan Medical Innovation Center §  Veenu Aulakh, Center for Care Innovation, Tides Foundation THANK YOU! §  Maria Ly, Skimble §  Borna Safabakhsh, Agile Diagnosis §  Ryan Panchadsaram, Pipette §  Rachel Kalmar, Senstore §  Andrey Ostrovsky, Care at Hand §  Michael Pan, Nephosity §  Amy Sheng, CellScope §  Sean Duffy, Omada Health §  Brian Chiko, Cognitive Health Innovations §  Jonathon Feit, Beyond Lucid §  Shenly Glenn, New Company §  Founding team, Reify Health Thank you to the following people for their valuable insights: A R O C K R E P O R T B Y